Sugi Predict

Sugi Predict / Compounds / SCHEMBL6696306

SCHEMBL6696306

SCHEMBL6696306

CC(c1cc(CC2CCOCC2)cc2c(=O)c(C(=O)NCc3ccc(Cl)cc3)nn(C)c12)[C@@]1(O)CCCC[C@H]1C

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.36
▸ THRB P10828 2/20 0.36
▸ POLA1 P09884 2/20 0.36
▸ KCNH2 Q12809 7/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ ABCB1 P08183 1/20 0.33
▸ GALR3 O60755 1/20 0.33
▸ NR2F2 P24468 1/20 0.33
▸ RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6690714 0.84 LMNA (0.37) LMNATHRBKMT2AMAPTSMN1; SMN2
SCHEMBL6696310 0.84 POLA1 (0.36) LMNATHRBPOLA1KCNH2KMT2A
SCHEMBL6691685 0.83 POLA1 (0.36) LMNATHRBPOLA1KCNH2KMT2A
SCHEMBL6691688 0.83 POLA1 (0.36) LMNATHRBPOLA1KCNH2KMT2A
SCHEMBL6695578 0.82 ABCB1 (0.40) THRBPOLA1KCNH2MAPTSMN1; SMN2
SCHEMBL6691101 0.78 POLA1 (0.51) POLA1KCNH2KMT2AMEN1SMN1; SMN2
SCHEMBL6694017 0.77 POLA1 (0.40) LMNATHRBPOLA1KCNH2KMT2A
SCHEMBL6690157 0.77 KCNH2 (0.42) POLA1KCNH2KMT2AMEN1MAPT
SCHEMBL7086001 0.77 POLA1 (0.34) LMNATHRBPOLA1KCNH2KMT2A
SCHEMBL6691018 0.76 KCNH2 (0.42) POLA1KCNH2KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067947-A1 Method of preventing or treating atherosclerosis or restenosis WATHEN MICHAEL W 2004-04-08 — — US claimed
EP-1265873-B1 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS UPJOHN CO (US) 2003-10-15 — — EP claimed
US-6624160-B2 Especially infections of herpes simplex virus type 1, 2, 6, 7, or 8, varicella zoster virus, human cytomegalovirus or epstein-Barr virus; enzyme inhibitors of virus DNA polymerase PHARMACIA & UPJOHN CO. 2003-09-23 — — US claimed
US-20020045619-A1 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-04-18 — — US claimed
US-20040067947-A1 Method of preventing or treating atherosclerosis or restenosis WATHEN MICHAEL W 2004-04-08 — — US disclosed
EP-1265873-B1 4-OXO-1,4-DIHYDRO-3-CINNOLINECARBOXAMIDES AS ANTIVIRAL AGENTS UPJOHN CO (US) 2003-10-15 — — EP disclosed
US-20020045619-A1 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045619-A1 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, EIF2AK2 LMNA 2648/4885THRB 4673/4885POLA1 219/4885
US-20040067947-A1 Method of preventing or treating atherosclerosis or restenosis LDLR, MSR1, NR1H2 LMNA 528/4885THRB 1519/4885POLA1 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.